DK2850189T3 - Sammensætninger og fremgangsmåder til modulering af genekspression - Google Patents

Sammensætninger og fremgangsmåder til modulering af genekspression Download PDF

Info

Publication number
DK2850189T3
DK2850189T3 DK13791343.0T DK13791343T DK2850189T3 DK 2850189 T3 DK2850189 T3 DK 2850189T3 DK 13791343 T DK13791343 T DK 13791343T DK 2850189 T3 DK2850189 T3 DK 2850189T3
Authority
DK
Denmark
Prior art keywords
homo sapiens
utrn
sapiens
sequence
nucleotides
Prior art date
Application number
DK13791343.0T
Other languages
English (en)
Inventor
Arthur M Krieg
Romesh Subramanian
James Mcswiggen
Jeannie T Lee
Original Assignee
Translate Bio Ma Inc
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49584310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2850189(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Translate Bio Ma Inc, Massachusetts Gen Hospital filed Critical Translate Bio Ma Inc
Application granted granted Critical
Publication of DK2850189T3 publication Critical patent/DK2850189T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (19)

1. Fremgangsmåde til at vælge et kandidat-oligonukleotid til at aktivere ekspression af et målgen, hvilken fremgangsmåde omfatter: at vælge en PRC2-associeret region i en første nukleotidsekvens, hvor den første nukleotidsekvens er placeret i en position i et første kromosom mellem 50 kilobaser opstrøms af en 5'-ende af målgenet og 50 kilobaser nedstrøms af en 3'-ende af målgenet, hvor den PRC2-associerede region er en region af et RNA, der er beskyttet mod en nuklease i et RNA-immunopræcipitationsassay, der anvender et antistof som er målrettet en komponent af PRC2; at bestemme en anden nukleotidsekvens der er komplementær til mindst 8 på hinanden følgende nukleotider af den PRC2-associerede region; og at vælge som kandidat-oligonukleotidet, et enkeltstrenget oligonukleotid omfattende den anden nukleotidsekvens, hvor oligonukleotidet har mindst ét af følgende kendetegn: a) en sekvens: 5'-X-Y-Z, hvor X er et hvilket som helst nukleotid, Y er en nukleotidsekvens på 6 nukleotider i længde, der ikke er en seed-sekvens af et humant microRNA, og Z er en nukleotidsekvens på 1 til 23 nukleotider i længde, hvor X er forankret ved den 5'-ende af oligonukleotidet; b) en sekvens, der ikke omfatter tre eller flere på hinanden følgende guanosinnukleotider; c) en sekvens, der er komplementær til en PRC2-associeret region, som koder for et RNA, der danner en sekundær struktur omfattende mindst to enkeltstrengede sløjfer; eller d) en sekvens, der har større end 60 % G-C-indhold; hvor det enkeltstrengede oligonukleotid er 8 til 30 nukleotider i længde.
2. Fremgangsmåden ifølge krav 1, hvor oligonukleotidet har mindst to af kendetegnene a), b), c) og d).
3. Fremgangsmåden ifølge krav 1, hvor oligonukleotidet har mindst tre kendetegn af a), b), c) og d).
4. Fremgangsmåde til at vælge et sæt af oligonukleotider, der er beriget i oligonukleotider som aktiverer ekspression af et målgen, hvilken fremgangsmåde omfatter: at vælge en PRC2-associeret region i en første nukleotidsekvens der er placeret i en position i et første kromosom mellem 50 kilobaser opstrøms af en 5'-ende af målgenet og 50 kilobaser nedstrøms af en 3'-ende af målgenet, hvor den PRC2-associerede region er en region af et RNA, der er beskyttet mod en nuklease i et RNA-immunopræcipitationsassay, der anvender et antistof som er målrettet en komponent af PRC2; at vælge et sæt af oligonukleotider, hvor hvert oligonukleotid i sættet omfatter en anden nukleotidsekvens der er komplementær til mindst 8 på hinanden følgende nukleotider af den PRC2-associerede region, og har mindst ét af de følgende kendetegn: a) en sekvens: 5'-X-Y-Z, hvor X er et hvilket som helst nukleotid, Y er en nukleotidsekvens på 6 nukleotider i længde, der ikke er en human seed-sekvens af et microRNA, og Z er en nukleotidsekvens på 1 til 23 nukleotider i længde, hvor X er forankret ved den 5'-ende af oligonukleotidet; b) en sekvens, der ikke omfatter tre eller flere på hinanden følgende guanosinnukleotider; c) en sekvens, der er komplementær til en PRC2-associeret region, som koder for et RNA, der danner en sekundær struktur omfattende mindst to enkeltstrengede sløjfer; og/eller d) en sekvens, der har større end 60 % G-C-indhold; og hvor sættet af oligonukleotider er beriget i oligonukleotider der aktiverer ekspression af et målgen; hvor hver af oligonukleotiderne er 8 til 30 nukleotider i længde.
5. Fremgangsmåden ifølge krav 4, hvor hver af oligonukleotiderne i sættet deler mindst to af kendetegnene a), b), c) og d).
6. Fremgangsmåden ifølge krav 4, hvor hver af oligonukleotiderne i sættet deler mindst tre af kendetegnene a), b), c) og d).
7. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 6, hvor det første kromosom er et kromosom af en første art, og hvor fremgangsmåden yderligere omfatter at bestemme at den anden nukleotidsekvens er komplementær til en anden region af et andet kromosom af en anden art, hvor den anden region er placeret mellem 50 kilobaser opstrøms af en 5'-ende af en homolog af målgenet og 50 kilobaser nedstrøms af en 3'-ende af homologen af målgenet.
8. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 7, hvor den første nukleotidsekvens er placeret på strengen af det første kromosom omfattende sense-strengen af målgenet eller den første nukleotidsekvens er placeret på strengen af det første kromosom omfattende antisense-strengen af målgenet.
9. Enkeltstreng et oligonukleotid til anvendelse i behandlingen afen sygdom, hvor behandlingen involverer at opregulere ekspression af et gen målrettet af det PRC2-bindende RNA og hvor det enkeltstrengede oligonukleotid omfatter en region af komplementaritet der er komplementær med mindst 8 på hinanden følgende nukleotider afen PRC2-associeret region placeret i et første kromosom mellem 50 kilobaser opstrøms afen 5'-ende af et målgen og 50 kilobaser nedstrøms af en 3'-ende af målgenet, hvor den PRC2-associerede region er en region af et RNA, der er beskyttet mod en nuklease i et RNA- immunopræcipitationsassay, der anvender et antistof som er målrettet en komponent af PRC2, og hvor oligonukleotidet har mindst én af: a) en sekvens omfattende 5'-X-Y-Z, hvor X er et hvilket som helst nukleotid, Y er en nukleotidsekvens på 6 nukleotider i længde, der ikke er en human seed-sekvens af et microRNA, og Z er en nukleotidsekvens på 1 til 23 nukleotider i længde; b) en sekvens, der ikke omfatter tre eller flere på hinanden følgende guanosinnukleotider; c) en sekvens, der er komplementærtil en PRC2-associeret region, som koder for et RNA, der danner en sekundær struktur omfattende mindst to enkeltstrengede sløjfer; og/eller d) en sekvens, der har større end 60 % G-C-indhold; hvor oligonukleotidet er 8 til 30 nukleotider i længde.
10. Enkeltstrenget oligonukleotid til anvendelse ifølge krav 9 hvor (a) sygdommen er kræft eller en stofskifte- eller luftvejssygdom eller (b) anvendelsen omfatter pulmonær levering og, eventuelt, sygdommen er en sygdom i lungerne.
11. Det enkeltstrengede oligonukleotid til anvendelse ifølge krav 9 eller 10, hvor oligonukleotidet har mindst to af kendetegnene a), b), c) og d).
12. Det enkeltstrengede oligonukleotid til anvendelse ifølge krav 9 eller 10, hvor oligonukleotidet har mindst tre af kendetegnene a), b), c) og d).
13. Det enkeltstrengede oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 9 til 12, hvor de mindst 8 på hinanden følgende nukleotider af den PRC2-associerede region i strengen af kromosomet omfattende sense-strengen af målgenet, eller hvor de mindst 8 på hinanden følgende nukleotider af den PRC2-associerede region i strengen af kromosomet omfattende antisense-strengen af målgenet.
14. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 8 eller det enkeltstrengede oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 9 til 13, hvor den PRC2-associerede region (a) er opstrøms af den 5'-ende af målgenet; (b) er nedstrøms af den 3'-ende af målgenet; (c) er i et intron af målgenet; (d) er i et exon af målgenet; eller (e) spænder over en intron-exon-forbindelse, en 5'-UTR-exon-forbindelse eller en 3'-UTR-exon-forbindelse af målgenet.
15. Det enkeltstrengede oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 9 til 14, hvor mindst ét nukleotid af oligonukleotidet er en nukleotid-analog.
16. Det enkeltstrengede oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 9 til 15, hvor mindst ét nukleotid af oligonukleotidet omfatter en 2' O-methyl; eller hvor oligonukleotidet omfatter mindst ét ribonukleotid, mindst ét deoxyribonukleotid, eller mindst ét broforbundet nukleotid, eventuelt hvor det broforbundne nukleotid er et LNA-nukleotid, et cEt-nukleotid eller en ENA-nukleotid-analog.
17. Det enkeltstrengede oligonukleotid til anvendelse ifølge krav 15, hvor nukleotiderne af oligonukleotidet omfatter: a) alternerende deoxyribonukleotider og 2'-fluor-deoxyribonukleotider; b) alternerende deoxyribonukleotider og 2'-O-methyl-nukleotider; c) alternerende deoxyribonukleotider og ENA-nukleotid-analoger; d) alternerende deoxyribonukleotider og LNA-nukleotider; eller e) alternerende LNA-nukleotider og 2'-O-methyl-nukleotider.
18. Det enkeltstrengede oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 9 til 17, yderligere omfattende phosphorthioat-internukleotidkoblingermellem mindst to nukleotider, eventuelt omfattende phosphorthioat-internukleotidkoblinger mellem alle nukleotider.
19. Det enkeltstrengede oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 9-18, hvor behandlingen af en sygdom er til behandling af en lidelse associeret med mindskede niveauer af et målgen hos et individ.
DK13791343.0T 2012-05-16 2013-05-16 Sammensætninger og fremgangsmåder til modulering af genekspression DK2850189T3 (da)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201261647901P 2012-05-16 2012-05-16
US201261648051P 2012-05-16 2012-05-16
US201261647949P 2012-05-16 2012-05-16
US201261648058P 2012-05-16 2012-05-16
US201261647886P 2012-05-16 2012-05-16
US201261647925P 2012-05-16 2012-05-16
US201261647858P 2012-05-16 2012-05-16
US201261648041P 2012-05-16 2012-05-16
US201261648021P 2012-05-16 2012-05-16
US201261648016P 2012-05-16 2012-05-16
US201261719394P 2012-10-27 2012-10-27
US201361785832P 2013-03-14 2013-03-14
US201361785529P 2013-03-14 2013-03-14
US201361785885P 2013-03-14 2013-03-14
US201361785778P 2013-03-14 2013-03-14
US201361785956P 2013-03-14 2013-03-14
US201361786232P 2013-03-14 2013-03-14
PCT/US2013/041461 WO2013173652A1 (en) 2012-05-16 2013-05-16 Compositions and methods for modulating gene expression

Publications (1)

Publication Number Publication Date
DK2850189T3 true DK2850189T3 (da) 2019-02-25

Family

ID=49584310

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13791343.0T DK2850189T3 (da) 2012-05-16 2013-05-16 Sammensætninger og fremgangsmåder til modulering af genekspression

Country Status (10)

Country Link
US (2) US20150133362A1 (da)
EP (2) EP2850189B8 (da)
JP (1) JP2015518714A (da)
KR (1) KR102028784B1 (da)
CN (1) CN104583398A (da)
AU (1) AU2013262663A1 (da)
CA (1) CA2873809A1 (da)
DK (1) DK2850189T3 (da)
EA (1) EA201492114A1 (da)
WO (1) WO2013173652A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
EA201492119A1 (ru) * 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии apoa1 и abca1
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
DK2850186T3 (da) 2012-05-16 2019-04-08 Translate Bio Ma Inc Sammensætninger og fremgangsmåder til at modulere smn-genfamilie-ekspression
EP2850190B1 (en) * 2012-05-16 2020-07-08 Translate Bio MA, Inc. Compositions and methods for modulating mecp2 expression
WO2013173645A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating utrn expression
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
JP2016521556A (ja) * 2013-06-07 2016-07-25 ラナ セラピューティクス インコーポレイテッド Ｆｏｘｐ３発現を調節するための組成物及び方法
WO2015023941A1 (en) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides targeting euchromatin regions of genes
US10174328B2 (en) 2013-10-04 2019-01-08 Translate Bio Ma, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3256591A4 (en) 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
EP3256590A4 (en) * 2015-02-13 2018-10-03 Translate Bio Ma, Inc. Targeting oligonucleotides and uses thereof to modulate gene expression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
JP7130639B2 (ja) 2016-11-01 2022-09-05 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN106636120B (zh) * 2017-02-17 2019-08-30 中国人民解放军第三军医大学第三附属医院 可编码ArtRD蛋白基因及其蛋白和应用
EP3679138B1 (en) 2017-09-08 2023-03-22 MiNA Therapeutics Limited Hnf4a sarna compositions and methods of use
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
WO2020028533A1 (en) * 2018-08-01 2020-02-06 Yale University Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer
WO2020056404A1 (en) * 2018-09-14 2020-03-19 Gen Shinozaki Systems and methods for detection of delirium risk using epigenetic markers
CA3120534A1 (en) * 2018-12-29 2020-07-02 Ractigen Therapeutics Oligomeric nucleic acid molecule and use thereof
EP4017539A1 (en) 2019-08-19 2022-06-29 MiNA Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
US20240102023A1 (en) * 2019-10-14 2024-03-28 University Of Cincinnati Novel rna aptamer intervenes estrogen receptor interaction with coactivator med1 to overcome breast cancer metastasis
CN113444726B (zh) * 2021-06-28 2022-07-29 甘肃农业大学 一种与仔猪细菌性腹泻相关的lncRNA ALDB-898及其应用
CN114540498A (zh) * 2022-03-09 2022-05-27 厦门飞朔生物技术有限公司 一种基于dna甲基化的浸润性神经胶质瘤的分类装置

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552A (en) 1848-05-09 Paul stillman
US538A (en) 1837-12-26 Self-separating link for connecting railroad-cars and locomotives
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US4671638A (en) 1985-10-11 1987-06-09 Eastman Kodak Company Moving coil electromagnetic actuator and shutter employing same
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
DE3788914T2 (de) 1986-09-08 1994-08-25 Ajinomoto Kk Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
EP0455905B1 (en) 1990-05-11 1998-06-17 Microprobe Corporation Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
DE69126530T2 (de) 1990-07-27 1998-02-05 Isis Pharmaceutical, Inc., Carlsbad, Calif. Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
PT98562B (pt) 1990-08-03 1999-01-29 Sanofi Sa Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DE69132510T2 (de) 1990-11-08 2001-05-03 Hybridon, Inc. Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
CA2159629A1 (en) 1993-03-31 1994-10-13 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
EP0733059B1 (en) 1993-12-09 2000-09-13 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
AU4595399A (en) 1998-06-19 2000-01-10 Mcgill University Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US20050003369A1 (en) * 2002-10-10 2005-01-06 Affymetrix, Inc. Method for depleting specific nucleic acids from a mixture
FR2853663B1 (fr) * 2003-04-14 2007-08-31 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
WO2005001110A2 (en) 2003-05-29 2005-01-06 The Salk Institute For Biological Studies Transcriptional regulation of gene expression by small double-stranded modulatory rna
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
GB0324854D0 (en) 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
WO2006113246A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Small activating rna molecules and methods of use
AU2006266503B2 (en) 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
EP2641970B1 (en) 2005-11-17 2014-12-24 Board of Regents, The University of Texas System Modulation of gene expression by oligomers targeted to chromosomal DNA
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
JP2009536222A (ja) * 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
US20100216864A1 (en) 2006-10-09 2010-08-26 Ellen Marie Straarup RNA Antagonist Compounds for the Modulation of PCSK9
EP1942192A1 (en) * 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Use of a tailored recombinase for the treatment of retroviral infections
WO2008103761A2 (en) * 2007-02-20 2008-08-28 Sequenom, Inc. Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
CA2685444A1 (en) 2007-05-01 2008-11-06 Jesper Worm Rna antagonist compounds for the modulation of beta-catenin
US8268793B2 (en) 2007-05-11 2012-09-18 Santaris Pharma A/S RNA antagonist compounds for the modulation of HER3
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
MY156951A (en) 2007-10-04 2016-04-15 Santaris Pharma As Micromirs
US20110263687A1 (en) 2008-04-07 2011-10-27 Riken Rna molecules and uses thereof
US20110224280A1 (en) 2008-04-16 2011-09-15 Niels Fisker Nielsen Pharmaceutical Composition Comprising Anti PCSK9 Oligomers
EA201170131A1 (ru) 2008-07-03 2011-08-30 Сантарис Фарма А/С Соединения антагонистов phk для ингибирования экспрессии митохондриальной глицерин-3-фосфатацилтрансферазы 1 (mtgpat1)
KR20110031976A (ko) 2008-07-15 2011-03-29 엔즌 파마슈티칼스, 인코포레이티드 Ｇｌｉ２를 표적화하는 ｒｎａ 길항제
MY188457A (en) 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EP2370581B1 (en) 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CN102307997B (zh) 2008-12-04 2018-03-30 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
CN102317458B (zh) 2008-12-04 2018-01-02 库尔纳公司 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
EP2384197B1 (en) 2008-12-31 2016-04-06 Roche Innovation Center Copenhagen A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
EP2396408B1 (en) 2009-02-12 2017-09-20 CuRNA, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (ja) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
EP2421972A2 (en) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
ES2661787T3 (es) * 2009-05-01 2018-04-04 Curna, Inc. Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
CA2761152A1 (en) 2009-05-06 2010-11-11 Opko Curna, Llc Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
KR101742334B1 (ko) 2009-05-08 2017-06-01 큐알엔에이, 인크. Ｄｍｄ 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
EP2435571B1 (en) 2009-05-28 2016-12-14 CuRNA, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (en) 2009-06-26 2016-04-20 CuRNA, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CN101619312B (zh) 2009-07-10 2011-04-20 四川大学 人黑色素瘤细胞特异表达的长非编码rna序列及其用途
CN102762731B (zh) 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2464731B1 (en) 2009-08-11 2016-10-05 CuRNA, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
CA2771228C (en) 2009-08-21 2020-12-29 Opko Curna, Llc Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
US9023822B2 (en) 2009-08-25 2015-05-05 Curna, Inc. Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
WO2011025862A2 (en) 2009-08-28 2011-03-03 Curna, Inc. Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
WO2011038205A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
CN102712927B (zh) 2009-12-16 2017-12-01 库尔纳公司 通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病
CN102781480B (zh) 2009-12-23 2018-07-27 库尔纳公司 通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CN102770540B (zh) 2009-12-29 2017-06-23 库尔纳公司 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
CN102906264B (zh) 2010-01-04 2017-08-04 库尔纳公司 通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
JP6027893B2 (ja) 2010-01-11 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
NO2529015T3 (da) 2010-01-25 2018-04-14
WO2011097582A2 (en) 2010-02-08 2011-08-11 Opko Curna Llc Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
EP2553098B1 (en) 2010-04-02 2017-10-11 CuRNA, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
KR101900962B1 (ko) 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
EP2558578B1 (en) * 2010-04-13 2015-10-28 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
CA2798218A1 (en) 2010-05-03 2011-11-10 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
AR081209A1 (es) 2010-05-19 2012-07-04 Opko Curna Llc Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
WO2011146675A2 (en) 2010-05-19 2011-11-24 Opko Curna Llc Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2
US8980858B2 (en) 2010-05-26 2015-03-17 Curna, Inc. Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
NO2576783T3 (da) 2010-05-26 2018-04-28
US20120004278A1 (en) * 2010-06-18 2012-01-05 The Board Of Trustees Of The Leland Stanford Junior University Linc rnas in cancer diagnosis and treatment
WO2012012443A2 (en) 2010-07-19 2012-01-26 Bennett C Frank Modulation of dystrophia myotonica-protein kinase (dmpk) expression
WO2012018881A2 (en) * 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
WO2013080784A1 (ja) 2011-11-30 2013-06-06 シャープ株式会社 メモリ回路とその駆動方法、及び、これを用いた不揮発性記憶装置、並びに、液晶表示装置

Also Published As

Publication number Publication date
CA2873809A1 (en) 2013-11-21
US20150133362A1 (en) 2015-05-14
EP3511416A1 (en) 2019-07-17
AU2013262663A1 (en) 2015-01-22
EP2850189B1 (en) 2018-11-07
KR102028784B1 (ko) 2019-10-04
EA201492114A1 (ru) 2015-04-30
JP2015518714A (ja) 2015-07-06
US20150218560A1 (en) 2015-08-06
WO2013173652A1 (en) 2013-11-21
KR20160073885A (ko) 2016-06-27
EP2850189A1 (en) 2015-03-25
EP2850189A4 (en) 2016-01-06
EP2850189B8 (en) 2019-01-23
CN104583398A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
DK2850189T3 (da) Sammensætninger og fremgangsmåder til modulering af genekspression
US11788089B2 (en) Compositions and methods for modulating MECP2 expression
US10059941B2 (en) Compositions and methods for modulating SMN gene family expression
US10174328B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis
US20150141320A1 (en) Compositions and methods for modulating gene expression
US20150159161A1 (en) Compositions and methods for modulating pten expression
US10837014B2 (en) Compositions and methods for modulating SMN gene family expression
KR20180118259A (ko) 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법
US20150191722A1 (en) Compositions and methods for modulating apoa1 and abca1 expression
WO2013173601A1 (en) Compositions and methods for modulating bdnf expression
WO2013173635A1 (en) Compositions and methods for modulating gene expression
EP3004354A1 (en) Compositions and methods for modulating foxp3 expression
US20240050461A1 (en) Use of mirna-485 inhibitors for inducing hair growth
JP2024522216A (ja) インフラマソーム関連疾患または障害を治療するためのｍｉｒｎａ－４８５阻害剤の使用